Israel McKenzie stands for a portrait in Chattanooga, Tenn., on Tuesday, May 21, 2024. In 2023, the weight-loss drug Wegovy helped him shed 110 pounds in nine months, making him part of what new research shows is a sharp surge in the use of powerful medications to treat diabetes and obesity in adolescents and young adults. (AP Photo/Mike Stewart)
Israel McKenzie stands for a portrait in Chattanooga, Tenn., on Tuesday, May 21, 2024. In 2023, the weight-loss drug Wegovy helped him shed 110 pounds in nine months, making him part of what new research shows is a sharp surge in the use of powerful medications to treat diabetes and obesity in adolescents and young adults. (AP Photo/Mike Stewart)
FILE - This image provided by Novo Nordisk in January 2023, shows packaging for the company's Wegovy drug. Even as millions of older adults clamor for drugs such as Ozempic and Wegovy, monthly use of the medications known as GLP-1 receptor agonists soared nearly 600% between 2020 and 2023 in people under 25 – and as young as 12. (Novo Nordisk via AP, File)
Israel McKenzie stands for a portrait in Chattanooga, Tenn., on Tuesday, May 21, 2024. In 2023, the weight-loss drug Wegovy helped him shed 110 pounds in nine months, making him part of what new research shows is a sharp surge in the use of powerful medications to treat diabetes and obesity in adolescents and young adults. (AP Photo/Mike Stewart)
FILE - The injectable drug Ozempic is shown Saturday, July 1, 2023, in Houston. Even as millions of older adults clamor for drugs such as Ozempic and Wegovy, monthly use of the medications known as GLP-1 receptor agonists soared nearly 600% between 2020 and 2023 in people under 25 – and as young as 12. (AP Photo/David J. Phillip, File)